Targeted Temperature Management
Temperature control is an active treatment to achieve and maintain a specific body temperature of a patient for a certain period of time, in order to improve health outcomes.
Cardiac arrest or cardiac arrest is a health condition that affects 10,000 Swedes every year (outside hospitals), which means just over 27 people every day. Only about 10% survive.
In cardiac arrest, cardiopulmonary resuscitation (CPR) and an early shock from a defibrillator are vital. Mild hypothermia treatment at IVA increases the chance of survival.
Scientific evidence supports the use of temperature control for patients who have suffered from cardiac arrest. The international guidelines support both a body temperature of 33°C and 36°C (Nielsen et al, 2013)
The results from the TTM2 study, published in June 2021, show that the clinical health outcome is equivalent if you achieve normothermia and prevent the patient from exceeding a body temperature of about ≥37.8°C (Nielsen et al, 2021).
Temperature control lowers the body temperature and reduces fever levels. Temperature control slows down the metabolism and oxygen demand in the brain, reduces oxidative stress and fluid supply to the brain and reduces glutamate, potassium, calcium toxicity after oxygen deficiency and elevated body temperature.
The current indications for temperature control are cardiac arrest, intensive care patients with difficult-to-treat fever and treatment of hypoxic ischemic encephalopathy (HIE) after asphyxia at birth and are given as a supplement to the common treatment.
Most scientific research projects are ongoing in many different areas to find new indications where cooling treatment is beneficial. Some potential indications are: ischemic stroke, traumatic head injury, heart attack and sepsis.